Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Kidney Neoplasms. Found 90 abstracts

no pagination
Ahmad AE, Kutikov A, Finelli A. Needle Tract Seeding Following Renal Tumor Biopsy: Scarcely a Concern or a Concern to Scare?. Eur Urol. 2019 May;75(5):868-70.   PMCID: Editorial
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86.
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice. The Urologic clinics of North America. 2017 May;44(2):203-11.
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
Joshi SS, Uzzo RG. Renal Tumor Anatomic Complexity: Clinical Implications for Urologists. The Urologic clinics of North America. 2017 May;44(2):179-87.
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
Ristau BT, Correa AF, Uzzo RG, Smaldone MC. Active Surveillance for the Small Renal Mass: Growth Kinetics and Oncologic Outcomes. The Urologic clinics of North America. 2017 May;44(2):213-22.
Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU international. 2017 Dec;120(6):782-92.
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 Sep;2(9):1179-86.   PMCID: PMC5568541
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Kidney Neoplasms

Kidney Neoplasms Renal Cell Carcinoma Middle Aged Male drug therapy Female Aged pathology therapeutic use Antineoplastic Agents administration & dosage Adult mortality Treatment Outcome 80 and over Aged adverse effects Disease-Free Survival methods Survival Rate Kidney cancer surgery Retrospective Studies Sunitinib Pyrroles therapy antagonists & inhibitors Oral Administration Indoles Antineoplastic Combined Chemotherapy Protocols Tumor Burden diagnosis secondary Risk Factors Kaplan-Meier Estimate Adjuvant Chemotherapy analogs & derivatives Nephrectomy statistics & numerical data Niacinamide Renal mass Time Factors Renal cell carcinoma Biopsy Tumor Biomarkers renal cell carcinoma Double-Blind Method Monoclonal Antibodies Young Adult Nivolumab Phenylurea Compounds epidemiology Outcomes Immune checkpoint inhibitor Angiogenesis Inhibitors Prior Authorization Intention to Treat Analysis Socioeconomic Factors Vascular Endothelial Growth Factor A Age Factors Survival Analysis Targeted therapy Disease Progression blood Differential Diagnosis Amino acids Patient Readmission High-Volume Hospitals Active surveillance Intravenous Administration Health Services Accessibility Kinetics Pharmaceutical Services Insurance Metastatic renal cell carcinoma Raman spectroscopy Pazopanib Registries Prostatic Neoplasms Follow-Up Studies Biological Models etiology genetics Medullary Carcinoma #Kcsm cytology Perioperative Period Cancer survival Nephrometry score Sulfonamides hemorrhage Adolescent Blood Transfusion Case-Control Studies United States Urological Diagnostic Techniques Tryptophan carcinoma Sorafenib renal medullary carcinoma (RMC) nephrectomy Watchful Waiting Small renal mass Surgical Blood Loss Ipilimumab Quality of Life enzymology Histidine Neoplasm Proteins Tertiary Care Centers Immunotherapy Tumor complexity Monoclonal Antibodies-Humanized pharmacology Antiangiogenic Raman Spectrum Analysis Single-Blind Method standards clopidogrel Immunological Antineoplastic Agents Urology Deductibles and Coinsurance Programmed Cell Death 1 Receptor Clinical Decision-Making tissue diagnosis Axitinib Medical Assistance Neoplasm Staging Kidney Medical Oncology Cell Proliferation Risk Assessment Platelet Aggregation Inhibitors Growth kinetics Child aspirin prevention & control Low-Volume Hospitals Response Evaluation Criteria in Solid Tumors biopsy Clopidogrel Drug Administration Schedule kidney cancer Coronary Thrombosis Tyrosine kinase inhibitors Plasma Postoperative Hemorrhage Progression-Free Survival Triazines Biomarker Accuracy Facility volume
Last updated on Friday, January 03, 2020